- Conditions
- Adenocarcinoma, Prostate Neoplasms, Prostate Cancer, Renal Cell Carcinoma, Von Hippel Lindau Disease
- Interventions
- EM Tracking
- Device
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 3,894 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–39
of 15
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Von Hippel Lindau Disease
- Interventions
- Not listed
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Von Hippel Lindau Disease, Kidney Neoplasms
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 13 Years to 100 Years
- Enrollment
- 546 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Von Hippel-Lindau Syndrome, Renal Cell Carcinoma, Hemangioblastoma
- Interventions
- SU011248
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation, VHL Syndrome, VHL Gene Inactivation, VHL-Associated Renal Cell Carcinoma, VHL-Associated Clear Cell Renal Cell Carcinoma
- Interventions
- Belzutifan
- Drug
- Lead sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 8
- States / cities
- Bethesda, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
- Conditions
- VHL Pancreatic Neuroendocrine Tumors, Von Hippel-Lindau Disease, Neuroendocrine Tumors
- Interventions
- 68-Gallium DOTATATE
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 740 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2036
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hippel-Lindau Disease, Kidney Cancer
- Interventions
- 17 allylamino-17-demethoxygeldanamycin, 18 FDG (Fludeoxyglucose 18F), [15-O] H2O, EPL diluent
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Macular Degeneration, Diabetic Retinopathy, Hippel-Landau Disease, Mitochondria
- Interventions
- Feasibility Study - Imaging System
- Procedure
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Von Hippel-Lindau Disease, CNS Hemangioblastoma, Retinal Hemangioblastoma
- Interventions
- PTK787/ZK 222584
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Durham, North Carolina
- Conditions
- Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers
- Interventions
- Belzutifan
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Chicago, Illinois • Warrenville, Illinois + 10 more
- Conditions
- Von Hippel-Lindau Syndrome
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Coats' Disease, Idiopathic Retinal Telangiectasia, Retinal Angiomatous Proliferation, Polypoidal Choroidal Vasculopathy, Pseudoxanthoma Elasticum, Pathological Myopia, Multi-focal Choroiditis, Rubeosis Iridis, Von Hippel Lindau Disease, BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
- Interventions
- ranibizumab injection (0.5 mg)
- Drug
- Lead sponsor
- Manhattan Eye, Ear & Throat Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Von-Hippel Lindau, Kidney Disease, Chronic
- Interventions
- Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 16 Years to 99 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Von Hippel-Lindau Syndrome
- Interventions
- Ranibizumab, E10030
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Von Hippel-Lindau Disease
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland